Overview

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

Status:
Not yet recruiting

Trial end date:
2022-08-30

Target enrollment:

Participant gender:

Summary

The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care setting.

Phase:

Phase 4

Details

Lead Sponsor:

Scotmann Pharmaceuticals

Collaborator:

Rawalpindi Medical College

Treatments:

Apixaban